Magle Chemoswed Holding Ab (MAGLE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Magle Chemoswed Holding Ab (MAGLE) has a cash flow conversion efficiency ratio of -0.006x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-2.52 Million ≈ $-271.62K USD) by net assets (Skr395.84 Million ≈ $42.60 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Magle Chemoswed Holding Ab (MAGLE) market capitalisation for the company's overall valuation and market capitalisation.
Magle Chemoswed Holding Ab - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Magle Chemoswed Holding Ab's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Magle Chemoswed Holding Ab Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Magle Chemoswed Holding Ab ranked by their cash flow conversion efficiency. Explore MAGLE operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Regent Pacific Properties Inc
V:RPP
|
0.061x |
|
GIGLIO GROUP S.P.A. O.N.
F:5JR
|
N/A |
|
Future Enterprises Limited
NSE:FELDVR
|
-0.222x |
|
Spectra Systems Corp
LSE:SPSY
|
0.210x |
|
ZyVersa Therapeutics Inc.
NASDAQ:ZVSA
|
119.987x |
|
Hardide PLC
LSE:HDD
|
0.191x |
|
Accelerate Diagnostics Inc
NASDAQ:AXDX
|
0.090x |
|
Condmag Brasov
RO:COMI
|
0.067x |
Annual Cash Flow Conversion Efficiency for Magle Chemoswed Holding Ab (2017–2025)
The table below shows the annual cash flow conversion efficiency of Magle Chemoswed Holding Ab from 2017 to 2025. View Magle Chemoswed Holding Ab (MAGLE) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr395.84 Million ≈ $42.60 Million |
Skr-31.93 Million ≈ $-3.44 Million |
-0.081x | -286.53% |
| 2024-12-31 | Skr560.60 Million ≈ $60.33 Million |
Skr-11.70 Million ≈ $-1.26 Million |
-0.021x | -121.54% |
| 2023-12-31 | Skr158.22 Million ≈ $17.03 Million |
Skr15.33 Million ≈ $1.65 Million |
0.097x | +14.08% |
| 2022-12-31 | Skr146.77 Million ≈ $15.79 Million |
Skr12.47 Million ≈ $1.34 Million |
0.085x | -54.73% |
| 2021-12-31 | Skr138.79 Million ≈ $14.94 Million |
Skr26.04 Million ≈ $2.80 Million |
0.188x | +492.89% |
| 2020-12-31 | Skr116.12 Million ≈ $12.50 Million |
Skr-5.54 Million ≈ $-596.73K |
-0.048x | +23.40% |
| 2019-12-31 | Skr113.66 Million ≈ $12.23 Million |
Skr-7.08 Million ≈ $-762.46K |
-0.062x | -128.56% |
| 2018-12-31 | Skr50.67 Million ≈ $5.45 Million |
Skr11.06 Million ≈ $1.19 Million |
0.218x | -65.21% |
| 2017-12-31 | Skr42.98 Million ≈ $4.63 Million |
Skr26.96 Million ≈ $2.90 Million |
0.627x | -- |
About Magle Chemoswed Holding Ab
Magle Chemoswed Holding AB (publ), together with its subsidiaries, engages in research and development of pharmaceutical and medical device products in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; and benserazide hydrochloride… Read more